AR061663A1 - Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. - Google Patents

Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados.

Info

Publication number
AR061663A1
AR061663A1 ARP070102855A ARP070102855A AR061663A1 AR 061663 A1 AR061663 A1 AR 061663A1 AR P070102855 A ARP070102855 A AR P070102855A AR P070102855 A ARP070102855 A AR P070102855A AR 061663 A1 AR061663 A1 AR 061663A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
preparation
pharmaceutical compositions
processes
Prior art date
Application number
ARP070102855A
Other languages
English (en)
Inventor
Abraham Thomas
Ashok Bhausaheb Kadam
Suresh M Kadam
Shantaram Kashinath Phatangare
Deepak Vital V
V S Prasada Rao Lingam
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AR061663A1 publication Critical patent/AR061663A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sal farmacéuticamente aceptable del mismo, para el tratamiento de la diabetes Tipo 2.Composiciones farmacéuticas que lo contienen Reivindicacion 1: Un proceso para la preparacion de un compuesto de la formula 1, y esteroisomeros de los mismos, en donde X es un cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, arilo sustituido o no sustituido, aralquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, anillo heterocíclico sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, o heteroarilalquilo sustituido o no sustituido, y R es alquilo C1-4, que comprende el paso de condensar el compuesto de la formula 2 con un éster de ácido glioxálico.
ARP070102855A 2006-06-27 2007-06-27 Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. AR061663A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1009MU2006 2006-06-27
IN1008MU2006 2006-06-27
US80732706P 2006-07-13 2006-07-13
US83169706P 2006-07-17 2006-07-17

Publications (1)

Publication Number Publication Date
AR061663A1 true AR061663A1 (es) 2008-09-10

Family

ID=38626165

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102855A AR061663A1 (es) 2006-06-27 2007-06-27 Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados.

Country Status (5)

Country Link
US (1) US7893103B2 (es)
EP (1) EP2035395A2 (es)
AR (1) AR061663A1 (es)
TW (1) TW200808770A (es)
WO (1) WO2008001195A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8404727B2 (en) 2009-01-07 2013-03-26 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
PL2376447T3 (pl) * 2009-01-09 2018-04-30 Orchid Pharma Limited Inhibitory dipeptydylopeptydazy iv
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7639M (es) 1967-09-14 1970-02-02
ATE370943T1 (de) * 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
WO2004050654A1 (ja) * 2002-11-29 2004-06-17 Shionogi & Co., Ltd. ピロリジン化合物の合成とその塩
AU2003902260A0 (en) * 2003-05-09 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
EP1657237A1 (en) * 2003-08-18 2006-05-17 Taisho Pharmaceutical Co. Ltd. Process for production of cis-4-fluoro-l-proline derivatives
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
EP1799639B1 (en) 2004-10-12 2013-09-04 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation

Also Published As

Publication number Publication date
US20080076818A1 (en) 2008-03-27
WO2008001195A3 (en) 2008-05-22
WO2008001195A2 (en) 2008-01-03
US7893103B2 (en) 2011-02-22
TW200808770A (en) 2008-02-16
EP2035395A2 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR070459A1 (es) Derivados de 2-aza-biciclo- [2,2,1] heptano
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
BR112022006572A2 (pt) Inibidores orais do fator d do complemento
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
AR123784A1 (es) Derivados de tetrazol como inhibidores de trpa1
EA200900481A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
WO2009021957A3 (en) Tricyclic heterocyclic compounds as gaba a modulators
EA200900480A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
EA201000832A1 (ru) Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
EA201000867A1 (ru) Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции
SE0400440D0 (sv) Novel Cinnamic Amides
TH83713B (th) อนุพันธ์ 2-(ไซคลิกอะมิโนคาร์บอนิล)อินโดลีน และ ส่วนผสมทางเภสัชกรรมที่มีสารนี้อยู่
CR20240570A (es) Compuestos de cd73
AR134129A1 (es) COMPUESTOS TRICÍCLICOS COMO INHIBIDORES DE PI3Ka
BRPI0607087A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
FB Suspension of granting procedure